
BioLife Solutions BLFS
$ 19.0
-1.4%
Quarterly report 2025-Q3
added 11-06-2025
BioLife Solutions Interest Expense 2011-2026 | BLFS
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense BioLife Solutions
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 497 K | 1.3 M | 662 K | 289 K | - | 5 K | 5 K | 190 K | 100 K | - | 177 K | 742 K | 733 K | 671 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.3 M | 5 K | 448 K |
Quarterly Interest Expense BioLife Solutions
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 284 K | 247 K | 103 K | - | 97 K | 146 K | 253 K | - | 235 K | 384 K | 394 K | - | 142 K | -22 K | 131 K | - | -7 K | - | - | - | 3 K | - | 1 K | - | 1 K | 1 K | 3 K | - | 1 K | 1 K | 1 K | - | 1.08 K | 105 K | 83.3 K | - | 33.3 K | - | - | - | - | - | - | - | - | - | 177 K | - | 186 K | 186 K | 186 K | - | 186 K | 184 K | 179 K | - | 172 K | 165 K | 161 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 394 K | -22 K | 126 K |
Interest Expense of other stocks in the Medical instruments industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Baxter International
BAX
|
290 M | $ 16.47 | -1.08 % | $ 8.45 B | ||
|
Atrion Corporation
ATRI
|
149 | - | - | $ 810 M | ||
|
Alcon
ALC
|
204 M | $ 74.46 | -0.25 % | $ 40.4 B | ||
|
The Cooper Companies
COO
|
-16.4 M | $ 69.5 | -1.13 % | $ 13.8 B | ||
|
electroCore
ECOR
|
14.9 K | $ 7.04 | - | $ 59.7 K | ||
|
Ekso Bionics Holdings
EKSO
|
-26 K | $ 9.6 | -1.54 % | $ 23.3 M | ||
|
AtriCure
ATRC
|
683 K | $ 28.76 | -1.47 % | $ 1.37 B | ||
|
Glaukos Corporation
GKOS
|
13.6 M | $ 115.08 | -1.41 % | $ 5.57 B | ||
|
Haemonetics Corporation
HAE
|
-9.75 M | $ 58.1 | -0.54 % | $ 2.92 B | ||
|
Harvard Bioscience
HBIO
|
-2.66 M | $ 5.53 | - | $ 245 M | ||
|
iRhythm Technologies
IRTC
|
5.44 M | $ 115.36 | -1.59 % | $ 3.69 B | ||
|
Repro Med Systems
KRMD
|
9.91 K | $ 4.25 | -0.23 % | $ 196 M | ||
|
Masimo Corporation
MASI
|
300 K | $ 178.34 | -0.08 % | $ 9.51 B | ||
|
Microbot Medical
MBOT
|
2 K | $ 2.32 | -1.91 % | $ 106 M | ||
|
Milestone Scientific
MLSS
|
126 K | $ 0.29 | - | $ 23.8 M | ||
|
Envista Holdings Corporation
NVST
|
-2.3 M | $ 25.51 | -1.22 % | $ 4.29 B | ||
|
Pro-Dex
PDEX
|
533 K | $ 48.53 | - | $ 160 M | ||
|
ICU Medical
ICUI
|
93.3 M | $ 121.67 | -1.08 % | $ 3 B | ||
|
ResMed
RMD
|
3.2 M | $ 224.04 | -0.34 % | $ 32.7 B | ||
|
InfuSystem Holdings
INFU
|
1.4 M | $ 9.43 | - | $ 195 M | ||
|
Retractable Technologies
RVP
|
227 K | $ 0.71 | -0.07 % | $ 21.3 M | ||
|
Isoray
ISR
|
2 K | - | 0.03 % | $ 108 M | ||
|
STAAR Surgical Company
STAA
|
2.25 M | $ 21.44 | 2.29 % | $ 1.06 B | ||
|
Stereotaxis
STXS
|
2 K | $ 1.85 | -1.86 % | $ 168 M | ||
|
LeMaitre Vascular
LMAT
|
5.18 M | $ 109.83 | 0.61 % | $ 2.49 B | ||
|
Teleflex Incorporated
TFX
|
57 M | $ 114.86 | -0.2 % | $ 5.13 B | ||
|
Merit Medical Systems
MMSI
|
-2.39 M | $ 66.72 | -1.61 % | $ 3.95 B | ||
|
Utah Medical Products
UTMD
|
-120 K | $ 63.75 | 1.3 % | $ 207 M | ||
|
Predictive Oncology
POAI
|
3 | - | - | $ 31.1 M | ||
|
Pulse Biosciences
PLSE
|
-52 K | $ 21.68 | -5.49 % | $ 1.46 B | ||
|
West Pharmaceutical Services
WST
|
-1 M | $ 258.0 | 0.4 % | $ 18.7 B | ||
|
DENTSPLY SIRONA
XRAY
|
24 M | $ 11.45 | -1.63 % | $ 2.28 B | ||
|
STERIS plc
STE
|
8.4 M | $ 219.18 | -0.37 % | $ 21.6 B | ||
|
AngioDynamics
ANGO
|
4.94 M | $ 9.51 | -3.35 % | $ 389 M | ||
|
Becton, Dickinson and Company
BDX
|
613 M | $ 154.32 | -0.59 % | $ 44.4 B | ||
|
Nephros
NEPH
|
2 K | $ 2.81 | -1.75 % | $ 29.2 M | ||
|
OraSure Technologies
OSUR
|
229 K | $ 3.05 | -1.14 % | $ 224 M | ||
|
Repligen Corporation
RGEN
|
8.12 M | $ 116.46 | -0.42 % | $ 6.49 M |